Adenovirus diagnostic testing is the most widely used method for determining the presence of adenoviruses in a culture of healthy volunteers and is adapted from the polymerase chain reaction (PCR) method: a procedure by which DNA strands are broken down into smaller pieces, and then are subjected to amplification reactions with adenoviruses. Because adenoviruses do not copy themselves but rather undergo multiple copied copies during viral replication, several different sequences of adenoviruses will be identified by PCRs. If a suitable sequence is detected, it will be amplified and the resulting product isolated.
In the case of patients suspected of having adenovirus, the adenovirus diagnostic testing is done by a polymerase chain reaction (PCR) test that can be performed on the patients' blood samples. Adenoviruses that have been identified by PCR will be identified by the confirmation of specific antibodies against the virus. These specific antibodies will react against the viral copies on the strain of adenovirus in the blood samples and will provide an accurate diagnosis. Patients with suspected AD may be asked to undergo EVGI or MBO testing, both of which will confirm the diagnosis. Besides, EVGI will also provide results regarding the presence of a retrovirus in the patients' lymph nodes, and MBO testing will provide conclusive proof that the patients carry the retrovirus.
Market Dynamics
The main factor driving the adenovirus diagnostic testing market is the growth of the treatment monitoring and diagnostic sector. For instance, according to Policynet, in 2018 the global healthcare sector generated a revenue of approximately US$ 1.853 trillion. Additionally, the expansion of the healthcare sectors in the emerging economies is expected to propel the market growth of adenovirus diagnostic testing. Moreover, government bodies all over the world are investing in the research and development of the treatment monitoring market, which is estimated to boost the market.
However, less knowledge related to various treatments and diagnostics and the high cost associated with the diagnostic procedures are the main restraining factors hindering the growth of adenovirus diagnostic testing market.
This market is distributed in five regions that include Asia-Pacific, North America, Europe, Africa, and the Middle East, and Latin America. Among these, North America is expected to a significant share of the adenovirus diagnostic testing market, owing to the increased expansion of the healthcare sector and the increasing incidence rate of diseases such as pneumonia. For instance, according to the Centers for Disease Control and Prevention, in the U.S. around 1.3 million people suffer from pneumonia. The adenovirus diagnostic testing market in the Asia Pacific is estimated to witness significant growth owing to government initiatives for raising awareness about health concerns.
Competitive Analysis
Key operating in the adenovirus diagnostic testing market include bioMerieux, Abbott Laboratories, DiaSorin Inc., Qiagen N.V., Novartis AG, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Becton Dickinson and company, and Affymetrix, Inc.
In December 2020, AlloVir announced that the Food and Drug Administration has given clearance for ALVR106, which is an allogeneic, multi virus-specific T cell therapy.
No comments:
Post a Comment